## Peter M Izmirly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/212793/publications.pdf

Version: 2024-02-01

90 papers 6,712 citations

35 h-index 79541 **73** g-index

95 all docs 95 docs citations

95 times ranked 6556 citing authors

#	Article	IF	CITATIONS
1	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	2.9	1,098
2	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.5	759
3	Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. New England Journal of Medicine, 2020, 383, 85-88.	13.9	377
4	Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody–Associated Cardiac Manifestations of Neonatal Lupus. Circulation, 2012, 126, 76-82.	1.6	363
5	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nature Immunology, 2019, 20, 915-927.	7.0	275
6	Maternal and Fetal Factors Associated With Mortality and Morbidity in a Multi–Racial/Ethnic Registry of Anti-SSA/Ro–Associated Cardiac Neonatal Lupus. Circulation, 2011, 124, 1927-1935.	1.6	257
7	Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open″abel clinical trial. Arthritis and Rheumatism, 2010, 62, 1138-1146.	6.7	211
8	The clinical spectrum of autoimmune congenital heart block. Nature Reviews Rheumatology, 2015, 11, 301-312.	3.5	209
9	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases, 2021, 80, 1339-1344.	0.5	202
10	Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Annals of the Rheumatic Diseases, 2010, 69, 1827-1830.	0.5	192
11	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight, 2017, 2, .	2.3	164
12	Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis and Rheumatism, 2009, 60, 3091-3097.	6.7	135
13	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis and Rheumatology, 2017, 69, 2006-2017.	2.9	126
14	Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis and Rheumatism, 2010, 62, 1153-1157.	6.7	119
15	Mortality in Systemic Lupus Erythematosus: an Updated Review. Current Rheumatology Reports, 2016, 18, 21.	2.1	118
16	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	1.3	118
17	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Metaâ€Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis and Rheumatology, 2021, 73, 991-996.	2.9	114
18	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following <scp>SARS</scp> â€" <scp>CoV</scp> â€2 Vaccination. Arthritis and Rheumatology, 2022, 74, 284-294.	2.9	103

#	Article	IF	Citations
19	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology, 2020, 76, 292-302.	1.2	97
20	Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology, 2012, 51, 1086-1092.	0.9	96
21	COVIDâ€19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Diseaseâ€Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis and Rheumatology, 2020, 72, 1981-1989.	2.9	92
22	Prevention and Treatment In Utero of Autoimmune-Associated Congenital Heart Block. Cardiology in Review, 2014, 22, 263-267.	0.6	90
23	Neonatal Lupus Syndromes. Rheumatic Disease Clinics of North America, 2007, 33, 267-285.	0.8	84
24	Sex Differences in Systemic Lupus Erythematosus. Mayo Clinic Proceedings, 2020, 95, 384-394.	1.4	83
25	Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Annals of the Rheumatic Diseases, 2016, 75, 1161-1165.	0.5	81
26	Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. Journal of Experimental Medicine, 2021, 218, .	4.2	61
27	Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis. JCI Insight, 2020, 5, .	2.3	57
28	Leveraging the United States Epicenter to Provide Insights on COVIDâ€19 in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1971-1980.	2.9	51
29	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2018, 103, 1074-1082.	2.3	48
30	A protective Langerhans cellâ $\in$ "keratinocyte axis that is dysfunctional in photosensitivity. Science Translational Medicine, 2018, 10, .	5.8	48
31	Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2018, 47, 545-551.	1.6	47
32	Neonatal lupus. Current Opinion in Rheumatology, 2012, 24, 466-472.	2.0	44
33	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 1742-1749.	0.5	40
34	Umbilical cord blood levels of maternal antibodies reactive with p200 and fullâ€length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care and Research, 2012, 64, 1373-1381.	1.5	39
35	Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Current Opinion in Rheumatology, 2017, 29, 467-472.	2.0	39
36	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. Arthritis Care and Research, 2019, 71, 949-960.	1.5	38

#	Article	IF	CITATIONS
37	Autoimmune-mediated congenital heart block. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 64, 41-51.	1.4	38
38	Urine Proteomics and Renal <scp>Singleâ€Cell</scp> Transcriptomics Implicate Interleukinâ€16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	2.9	38
39	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.5	37
40	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.5	35
41	Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro–Associated Cardiac Neonatal Lupus. Journal of the American College of Cardiology, 2015, 66, 930-939.	1.2	32
42	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp> : Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	2.3	30
43	Systemic Autoimmune Disease Among Adults Exposed to the September 11, 2001 Terrorist Attack. Arthritis and Rheumatology, 2020, 72, 849-859.	2.9	29
44	Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatology, The, 2022, 4, e384-e387.	2.2	27
45	Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmunity Reviews, 2017, 16, 980-983.	2.5	25
46	Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology, 2008, 48, 513-519.	0.9	24
47	SLE: reconciling heterogeneity. Lupus Science and Medicine, 2019, 6, e000280.	1.1	23
48	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Science and Medicine, 2019, 6, e000344.	1.1	22
49	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. Arthritis Research and Therapy, 2020, 22, 191.	1.6	21
50	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. Lancet Rheumatology, The, 2021, 3, e585-e594.	2.2	18
51	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care and Research, 2020, 72, 233-242.	1.5	17
52	Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Lupus Science and Medicine, 2021, 8, e000614.	1.1	17
53	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008686.	2.1	16
54	Rapid aneurysm growth and rupture in systemic lupus erythematosus. , 2015, 6, 9.		15

#	Article	IF	Citations
55	Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. Life Science Alliance, 2021, 4, e202101180.	1.3	15
56	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. Journal of Rheumatology, 2022, 49, 388-397.	1.0	11
57	Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Arthritis and Rheumatology, 2017, 69, 785-790.	2.9	10
58	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. Rheumatology, 2019, 58, 2000-2008.	0.9	10
59	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000475.	1.1	10
60	Validation of Systemic Lupus Erythematosus Diagnosis as the Primary Cause of Renal Failure in the US Renal Data System. Arthritis Care and Research, 2017, 69, 599-604.	1.5	9
61	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatology, The, 2022, 4, e582-e585.	2.2	9
62	Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials.―by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45. Autoimmunity Reviews, 2014, 13, 70-72.	2.5	7
63	In search of an antibody specificity highly predictive of congenital heart block. Lupus Science and Medicine, 2016, 3, e000154.	1.1	7
64	SLE clinical trials: impact of missing data on estimating treatment effects. Lupus Science and Medicine, 2019, 6, e000348.	1.1	7
65	Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis. Journal of Rheumatology, 2012, 39, 510-515.	1.0	6
66	Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. Lupus Science and Medicine, 2018, 5, e000266.	1.1	6
67	Factors associated with long-term cardiac dysfunction in neonatal lupus. Annals of the Rheumatic Diseases, 2020, 79, 217-224.	0.5	6
68	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology, 2022, 61, 4335-4343.	0.9	6
69	Gut dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus. Gut Microbes, 2022, 14, .	4.3	6
70	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	1.1	5
71	No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. Clinical and Experimental Rheumatology, 2017, 35, 857-859.	0.4	4
72	Neonatal Lupus. , 2014, , 251-272.		3

#	Article	IF	Citations
73	COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study. JAAD International, 2022, 8, 31-33.	1.1	2
74	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. Arthritis Care and Research, 0, , .	1.5	2
75	Neonatal Lupus. , 2016, , 451-461.		1
76	CS-31â€Safety of hydroxychloroquine withdrawal in older adults with systemic lupus erythematosus. , 2018, , .		1
77	Neonatal Lupus. , 2019, , 486-498.		1
78	Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment. , 2021, , 507-519.		1
79	Hydroxychloroquine Toxicity. Journal of Clinical Rheumatology, 2020, Publish Ahead of Print, .	0.5	1
80	To Be or Not to Be Treated: That Is the Question in Managing a Fetus With Cardiac Injury Exposed to Antiâ€SSA/Ro. Journal of the American Heart Association, 0, , .	1.6	1
81	CS-04â€Associated factors of long-term cardiac dysfunction in a longitudinal cohort of neonatal lupus. , 2018, , .		0
82	$194\hat{a}\in$ Transcriptome analysis of skin fibroblasts derived from lupus nephritis patients demonstrates fibrotic and interferon-related cellular biomarkers. , 2019, , .		0
83	273â€Safety of research cores obtained from clinically indicated biopsies in the accelerating medicines partnership network. , 2019, , .		0
84	300â€Insights from single-cell RNA sequencing of skin and kidney in lupus nephritis. , 2019, , .		0
85	64â€ANA by indirect immunofluorescence alone rare in SLE and clinical phenotype of patients with ANA plus lupus associated antibodies is different than ANA alone. , 2019, , .		0
86	O8â€Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
87	Passively acquired lupus in the fetus and neonate. , 2021, , 325-363.		0
88	511â€Disease flares in lupus are concordant with <i>Ruminococcus Blautia Gnavus</i> blooms arising within unstable gut microbiota communities. , 2021, , .		0
89	901â€Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. , 2021, , .		0
90	1118â€Incidence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. , 2021, , .		0